Sage Therapeutics Inc
(FRA:SG7)
€
5.452
0.102 (1.91%)
Market Cap: 325.18 Mil
Enterprise Value: -211.07 Mil
PE Ratio: 0
PB Ratio: 0.61
GF Score: 49/100 SAGE Therapeutics Inc at Cowen Health Care Conference Transcript
Mar 06, 2023 / 03:30PM GMT
Release Date Price:
€38.68
(-1.63%)
Ritu Subhalaksmi Baral
TD Cowen, Research Division - MD & Senior Biotechnology Analyst
We're going to go ahead and get started. Thank you, everyone, for joining us for the Sage fireside chat at the TD Cowen Healthcare Conference this year.
With us, we have the CEO of Sage, Barry Greene, who most of you, I think, know quite well. I'm Ritu Baral, covering analyst -- moderating.
Questions & Answers
Ritu Subhalaksmi Baral
TD Cowen, Research Division - MD & Senior Biotechnology Analyst
Barry, do you want to give us just a few minutes on where we are in zuranolone's -- well, where Sage is, but also specifically where we are in zuranolone's clinical development and NDA review patent?
Barry E. Greene
Sage Therapeutics, Inc. - President, CEO & Director
Absolutely, Ritu. First of all, thanks for having us, and I appreciate the organizers for TD Cowen putting us in this enormous room that we're in. So thank you for that. It took me longer to get here than it took to get from my home to the
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot